SELENOP and neoplasm: To test this hypothesis, we simultaneously analysed three complementary biomarkers of Se status (total serum Se, SELENOP, GPx3) and conducted bulk RNA-sequencing of tumours of 1453 patients with a new diagnosis of primary invasive breast cancer.